A Phase II Study of Nimotuzumab in Patients with Unresectable Stage III Non-small Cell Lung Cancer

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080220796

Enrollment

Registered

2009-08-04

Start date

2009-08-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable stage III non-small cell lung cancer

Interventions

investigational material(s) Generic name etc : DE-766 INN of investigational material : Nimotuzumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with unresectable stage IIIA or IIIB of NSCLC Patients who are judged to be suitable for radical radiotherapy

Exclusion criteria

Exclusion criteria: Patients with another active malignancy Patients who have obvious pulmonary fibrosis or interstitial pneumonia by chest CT-scans Patients with severe or uncontrolled complications

Design outcomes

Primary

Measure	Time frame
Tolerability The proportion of patients who have completed all of the protocol-stipulated treatments	—

Secondary

Measure	Time frame
Safety, response rate, progression-free survival , progression-free survival rate, and survival rate NCI-CTC (ver.3.0), RECIST (ver. 1.1)	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026